Menu
Search
|

Menu

Close
X

NuVasive Inc NUVA.OQ (NASDAQ Stock Exchange Global Select Market)

47.55 USD
-- (--)
As of Feb 20
chart
Previous Close 47.55
Open --
Volume --
3m Avg Volume 329,745
Today’s High --
Today’s Low --
52 Week High 81.48
52 Week Low 44.62
Shares Outstanding (mil) 50.97
Market Capitalization (mil) 2,423.53
Forward P/E 40.00
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.11 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
758
FY16
962
FY15
811
EPS (USD)
FY17
1.075
FY16
0.685
FY15
1.269
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
40.00
35.76
Price to Sales (TTM)
vs sector
2.36
8.59
Price to Book (MRQ)
vs sector
3.21
5.23
Price to Cash Flow (TTM)
vs sector
13.35
26.13
Total Debt to Equity (MRQ)
vs sector
81.78
15.32
LT Debt to Equity (MRQ)
vs sector
76.49
11.95
Return on Investment (TTM)
vs sector
4.57
13.59
Return on Equity (TTM)
vs sector
8.88
15.20

EXECUTIVE LEADERSHIP

Gregory Lucier
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $800,000.00
Bonus: --
Rajesh Asarpota
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Joan Stafslien
Executive Vice President, General Counsel, Corporate Secretary, Since 2016
Salary: --
Bonus: --
Carol Cox
Executive Vice President - External Affairs and Corporate Marketing, Since 2015
Salary: --
Bonus: --
Peter Leddy
Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications, Since 2015
Salary: $203,076.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

7475 Lusk Blvd
SAN DIEGO   CA   92121-5707

Phone: +1858.9091800

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

SPONSORED STORIES